Financing will enable the completion of the ongoing Phase 1/2 clinical trial of INX-315 in patients with recurrent ...

New research from Dana-Farber Cancer Institute shows that a new class of drug results in cell death in cancers, such as small ...

Incyclix Bio, LLC, a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for the ...

Cyclin-dependent kinase 6 (CDK6) plays a crucial role in the G1 phase to S phase transition of the cell cycle. Aberrant activation of CDK6 has been linked with the development and progression of ...

Schrödinger has halted development of its cancer-fighting candidate SGR-2921 after two patients treated with the CDC7 inhibitor died in a Phase I trial.

Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis on June 24, 2025 ...